Condition
Adult Meningioma
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT00019578Phase 1Completed
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
NCT00045734Phase 2Completed
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
NCT00003590Phase 2CompletedPrimary
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Showing all 3 trials